Spotlight Medical Raises €6.2 Million Seed Round to Launch AI-Driven Cancer Prognosis Test
- Spotlight Medical raised €6.2 million in seed funding led by Kurma Partners and Heal Capital.
- The funds will commercialize Spotlight Medical's AI-based prognosis test for personalized cancer care.
French startup Spotlight Medical has raised €6.2 million in a seed funding round led by Kurma Partners and Heal Capital.
This funding will allow the startup to introduce its initial AI-driven prognosis test into clinical settings. This also marks it as an important step in commercializing AI-based cancer treatment solutions.
“We are thrilled to have the support of Kurma Partners and Heal Capital as we take this critical step towards transforming cancer treatment. This investment will accelerate our mission to harness the power of AI in analyzing patient data, providing physicians with the insights they need to make more informed treatment decisions,” said Sylvain Berlemont, CEO of Spotlight Medical.
Founded this year by Sylvain Berlemont, Marvin Lerousseau, and Grégoire Gessain, Spotlight Medical, develops clinical tests using patient data and advanced AI algorithms to improve precision in cancer treatment.
Newsletter
The corridor, every morning.
Funding rounds and cross-border capital moves, one email, five minutes.
They aim to provide the first AI-based solution for personalized cancer care, enhancing patient outcomes and quality of life through physician collaboration.
Founded in July 2009, Kurma Partners is a top European venture capital firm that funds healthcare and biotechnology innovation from early stages to growth capital. The firm operates funds like Kurma Biofund I, II, and III, Kurma Diagnostics, Kurma Diagnostics 2, and the new Kurma Growth Opportunities Fund.
Edited by Harshajit Sarmah
More in Funding
